// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Ileal pouch excision: A contemporary observational cohort

G Worley - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A ‘real-world’ retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis

V Kronsten - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Adalimumab

Response to IV steroid therapy in acute severe ulcerative colitis (ASUC) is not altered by admission to a tertiary referral centre: The NHS Lothian experience

T Manship - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international database

G Pellino - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Interstitial and granulomatous lung disease in inflammatory bowel disease patients

E Eliadou - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Comparison of disease burden of ulcerative colitis patients treated with biologics/biosimilars in remission and not in remission across the EU5

Y Lu - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Fatigue and its severity depends on demographic and clinical factors in the Polish population of patients with inflammatory bowel disease - results of a cross-sectional study

A Liebert - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Both the standard and a modified capsule endoscopy Lewis score of inflammation correlates with faecal calprotectin and small bowel tranit time

A Barnes - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improving the diagnosis of Crohn’s disease (CD) in patients presenting with perianal abscess to the emergency surgeons

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Day of admission results predict outcome in acute ulcerative colitis

R Grant - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party

C Brierley - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)

S Danese - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations

G Walker - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease

A Sazonovs - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Adalimumab

Transanal minimally invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with ulcerative colitis: a cohort study from the TaTME international database

G Pellino - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study

N A Kennedy - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

α4β7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages

L Schleier - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Shallow whole-genome sequencing predicts the future cancer risk of low-grade dysplastic lesions arising in ulcerative colitis

I Al Bakir - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM

W Reinisch - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study

U Kopylov - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Copyright © 2026. QuantiNova All rights reserved